- |||||||||| libvatrep oral (SAF312) / Novartis
Journal: Ocular Pharmacology and Toxicology of TRPV1 Antagonist SAF312 (Libvatrep). (Pubmed Central) - Sep 8, 2023 SAF312 is a potent, selective, and noncompetitive antagonist of hTRPV1 with an acceptable preclinical safety profile for use in future clinical trials. SAF312, which was safe and well tolerated without causing delay in wound healing after PRK in rabbits, may be a potential therapeutic agent for ocular surface pain.
- |||||||||| Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, libvatrep oral (SAF312) / Novartis, Lodonal (naltrexone low dose oral) / Immune Therap, Statera BioPharma
Journal: Ocular surface itch and pain: key differences and similarities between the two sensations. (Pubmed Central) - Aug 31, 2023 Identifying contributors to abnormal ocular sensations is vital for precise medical care. Novel therapeutics for these conditions aim to improve patient outcomes and quality of life.
|